The expert has no doubts: this cancer can be cured effectively
Author: PW • Source: Rynek Zdrowia • Published: July 10, 2025 11:40
Patients who have been treated for hormone-dependent, HER2-negative breast cancer also face a certain risk of recurrence. "As patients, we must be aware of this. We strive to ensure that cyclib treatment is available for all groups of women with this type of cancer, as indicated," emphasizes Anna Kupiecka, president of the OnkoCafe - Razemlepszy Foundation.
- A group of patients with hormone-dependent, HER2-negative breast cancer have been secured for cyclib treatment. This applies to women at high risk of cancer recurrence.
- Patients treated with this drug in combination with hormone therapy live longer without disease progression and have a better chance of survival
- Women with early detection of hormone-dependent, HER2-negative breast cancer also have a certain risk of disease recurrence.
- It is therefore important that the reimbursed cyclib is also available in this group of patients, says Anna Kupiecka, president of the OnkoCafe - Razemlepszy Foundation.
- As he emphasizes, after curing breast cancer, a woman should still remain oncologically vigilant
"Many women with cured hormone-dependent, HER2-negative breast cancer, including early stage breast cancer, are not fully aware that the disease can recur even long after the first stage of treatment. Therefore, building awareness on this topic is crucial," notes Anna Kupiecka, president of the OnkoCafe - Razemlepszy Foundation and vice president of the Polish Oncology Federation.
In an interview with Rynek Zdrowia, she adds that it is necessary to make modern drugs available in all cases of hormone-dependent HER2-negative breast cancer, as indicated.
*The conversation was recorded during the Women's Health Forum (Katowice, June 9-10, 2025).
Copyrighted material - reprint rules are specified in the regulations .
rynekzdrowia
